Search research articles
Contact Us
Filters
Showing results (141-150 of 169) with videos related to
Page
of 17
Sort By:
Nature Communications
|
August 8, 2019
Author Correction: Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion
Van T M Nguyen, Iros Barozzi, Monica Faronato, et al.
Antioxidants & Redox Signaling
|
April 22, 2015
Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer
Ferdinando Chiaradonna, Iros Barozzi, Claudia Miccolo, et al.
Nature Communications
|
August 27, 2024
LSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8<sup>+</sup> T cell responsiveness
Isabella Pallavicini, Teresa Maria Frasconi, Carlotta Catozzi, et al.
European Journal of Medicinal Chemistry
|
May 7, 2022
Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models
Martina Menna, Francesco Fiorentino, Biagina Marrocco, et al.
Journal of Medicinal Chemistry
|
June 12, 2014
Cinnamic anilides as new mitochondrial permeability transition pore inhibitors endowed with ischemia-reperfusion injury protective effect in vivo
Daniele Fancelli, Agnese Abate, Raffaella Amici, et al.
The Journal of Clinical Investigation
|
November 29, 2016
Dual modulation of MCL-1 and mTOR determines the response to sunitinib
Mohamed Elgendy, Amal Kamal Abdel-Aziz, Salvatore Lorenzo Renne, et al.
Journal of Medicinal Chemistry
|
December 19, 2009
Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors
Florian Thaler, Andrea Colombo, Antonello Mai, et al.
Journal of Medicinal Chemistry
|
February 11, 2017
Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structure-Activity Relationship
Paola Vianello, Luca Sartori, Federica Amigoni, et al.
Nature Communications
|
January 27, 2024
Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion
Rani Pallavi, Elena Gatti, Tiphanie Durfort, et al.
Cancer Discovery
|
May 15, 2016
In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype
Daniela Bossi, Angelo Cicalese, Gaetano I Dellino, et al.
Page
of 17
Search research articles
Search
Showing results (141-150 of 169) with videos related to
Sort By:
Page
of 17
Nature Communications
|
August 8, 2019
Author Correction: Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion
Van T M Nguyen, Iros Barozzi, Monica Faronato, et al.
Antioxidants & Redox Signaling
|
April 22, 2015
Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer
Ferdinando Chiaradonna, Iros Barozzi, Claudia Miccolo, et al.
Nature Communications
|
August 27, 2024
LSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8<sup>+</sup> T cell responsiveness
Isabella Pallavicini, Teresa Maria Frasconi, Carlotta Catozzi, et al.
European Journal of Medicinal Chemistry
|
May 7, 2022
Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models
Martina Menna, Francesco Fiorentino, Biagina Marrocco, et al.
Journal of Medicinal Chemistry
|
June 12, 2014
Cinnamic anilides as new mitochondrial permeability transition pore inhibitors endowed with ischemia-reperfusion injury protective effect in vivo
Daniele Fancelli, Agnese Abate, Raffaella Amici, et al.
The Journal of Clinical Investigation
|
November 29, 2016
Dual modulation of MCL-1 and mTOR determines the response to sunitinib
Mohamed Elgendy, Amal Kamal Abdel-Aziz, Salvatore Lorenzo Renne, et al.
Journal of Medicinal Chemistry
|
December 19, 2009
Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors
Florian Thaler, Andrea Colombo, Antonello Mai, et al.
Journal of Medicinal Chemistry
|
February 11, 2017
Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structure-Activity Relationship
Paola Vianello, Luca Sartori, Federica Amigoni, et al.
Nature Communications
|
January 27, 2024
Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion
Rani Pallavi, Elena Gatti, Tiphanie Durfort, et al.
Cancer Discovery
|
May 15, 2016
In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype
Daniela Bossi, Angelo Cicalese, Gaetano I Dellino, et al.
Page
of 17